Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Erasca, Inc.ERAS · Entity 3796 | Chief Medical Officer | March 04, 2026 | March 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Erasca, Inc.
Report date March 04, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-03-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-03-04 · Exercise / conversion · Acquired 20,000 · Balance 20,000 F1: The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 30, 2024. Row 2 · 2026-03-04 · Sale · Disposed 20,000 · Balance 0 F1: The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 30, 2024. F2: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.10. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.70 · Expires 2034-02-04 | Direct | 515,800 |
Reported balance
After 2025-03-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-03-04 · Exercise / conversion · Disposed 20,000 · Balance 515,800 F1: The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 30, 2024. F3: 1/48th of the shares subject to the option vest monthly, with vesting starting on February 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 30, 2024.
F2: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.10. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: 1/48th of the shares subject to the option vest monthly, with vesting starting on February 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 6, 2026 14:00 UTC | Erasca, Inc. ERAS · Entity 3796 | SaleCommon Stock | 20,000 | $15.04 | $300,760.00 |
DisclosureSEC source: 0001193125-26-095181 · ownership.xml · nonDerivative · entry 2 Morris Shannon · CIK 0001973527 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 30, 2024. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.10. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2026 Filed Mar 6, 2026 14:00 UTC | Erasca, Inc. ERAS · Entity 3796 | Exercise / conversionCommon Stock | 20,000 | $1.70 | $34,000.00 |
DisclosureSEC source: 0001193125-26-095181 · ownership.xml · nonDerivative · entry 1 Morris Shannon · CIK 0001973527 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 30, 2024. Read SEC document |
| January 29, 2026 Filed Jan 30, 2026 14:02 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock option (right to buy) · Derivative | 625,000 | $0.00 Strike: $10.31 | $0.00 |
DisclosureSEC source: 0001193125-26-030619 · ownership.xml · derivative · entry 1 Morris Shannon · CIK 0001973527 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 625,000 Underlying: Common Stock · 625,000 shares Expires 2036-01-29 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly on the 29th day of each month (or the last day of February), starting in February 2026, subject to the Reporting Person's continuous service to the issuer on each such vesting date. Read SEC document |
| March 04, 2025 Filed Mar 6, 2026 14:00 UTC | Erasca, Inc. ERAS · Entity 3796 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001193125-26-095181 · ownership.xml · derivative · entry 3 Morris Shannon · CIK 0001973527 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 515,800 Underlying: Common Stock · 20,000 shares Expires 2034-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on June 30, 2024. F3 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly, with vesting starting on February 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 03, 2025 Filed Feb 5, 2025 14:20 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock option (right to buy) · Derivative | 780,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0000950170-25-014195 · ownership.xml · derivative · entry 1 Morris Shannon · CIK 0001973527 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 780,000 Underlying: Common Stock · 780,000 shares Expires 2035-02-02 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly, with vesting starting on February 1, 2025, subject to the Reporting Person's continuous service to the issuer on each such vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 12:48 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (right to buy) · Derivative | 137,142 | $0.00 Strike: $2.03 | $0.00 |
DisclosureSEC source: 0001209191-24-005925 · doc4.xml · derivative · entry 1 Morris Shannon · CIK 0001973527 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,142 Underlying: Common Stock · 137,142 shares Expires 2034-06-19 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly, with vesting starting on June 20, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| February 05, 2024 Filed Feb 7, 2024 23:48 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (right to buy) · Derivative | 535,800 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0001209191-24-002965 · doc4.xml · derivative · entry 1 Morris Shannon · CIK 0001973527 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 535,800 Underlying: Common Stock · 535,800 shares Expires 2034-02-04 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly, with vesting starting on February 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| April 10, 2023 Filed Apr 14, 2023 00:26 UTC | Erasca, Inc. ERAS · Entity 3796 | GrantStock Option (Right to Buy) · Derivative | 375,000 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001209191-23-024257 · doc4.xml · derivative · entry 1 Morris Shannon · CIK 0001973527 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2033-04-09 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly following April 10, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.